PHARMACEUTICAL 2026

Genelux Corp
Rank 140 of 178



PHARMACEUTICAL 2026

Genelux Corp
Rank 140 of 178

The relative strengths and weaknesses of Genelux Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Genelux Corp compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 7.8% points.The greatest weakness of Genelux Corp is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 91% points.

The company's Economic Capital Ratio, given in the ranking table, is 138%, being 91% points below the market average of 229%.

Input Variable	Value in 1000 USD
Assets, Current	15,130
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,225
Liabilities, Non-Current	1,258
Other Assets	1,727
Other Compr. Net Income	-55
Other Expenses	0
Other Liabilities	0
Other Net Income	1,069
Other Revenues	8.0
Property and Equipment	2,170
Research and Development	19,851
Selling, General and Administrative Expense	13,371

Output Variable	Value in 1000 USD
Assets	19,027
Liabilities	7,483
Expenses	33,222
Revenues	8.0
Stockholders Equity	11,544
Net Income	-32,145
Comprehensive Net Income	-32,172
BaseVar	30,432
ECR before LimitedLiability	-53%
Economic Capital Ratio	138%